% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Venskutonyt:472478,
      author       = {Venskutonytė, Raminta and Koh, Ara and Stenström, Olof
                      and Khan, Muhammad Tanweer and Lundqvist, Annika and Akke,
                      Mikael and Bäckhed, Fredrik and Lindkvist-Petersson, Karin},
      title        = {{S}tructural characterization of the microbial enzyme
                      urocanate reductase mediating imidazole propionate
                      production},
      journal      = {Nature Communications},
      volume       = {12},
      number       = {1},
      issn         = {2041-1723},
      address      = {[London]},
      publisher    = {Nature Publishing Group UK},
      reportid     = {PUBDB-2021-05031},
      pages        = {1347},
      year         = {2021},
      abstract     = {The human microbiome can produce metabolites that modulate
                      insulin signaling. Type 2 diabetes patients have increased
                      circulating concentrations of the microbially produced
                      histidine metabolite, imidazole propionate (ImP) and
                      administration of ImP in mice resulted in impaired glucose
                      tolerance. Interestingly, the fecal microbiota of the
                      patients had increased capacity to produce ImP, which is
                      mediated by the bacterial enzyme urocanate reductase (UrdA).
                      Here, we describe the X-ray structures of the ligand-binding
                      domains of UrdA in four different states, representing the
                      structural transitions along the catalytic reaction pathway
                      of this unexplored enzyme linked to disease in humans. The
                      structures in combination with functional data provide key
                      insights into the mechanism of action of UrdA that open new
                      possibilities for drug development strategies targeting type
                      2 diabetes.},
      cin          = {EMBL-User},
      ddc          = {500},
      cid          = {I:(DE-H253)EMBL-User-20120814},
      pnm          = {6G3 - PETRA III (DESY) (POF4-6G3)},
      pid          = {G:(DE-HGF)POF4-6G3},
      experiment   = {EXP:(DE-H253)P-P13-20150101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33649331},
      UT           = {WOS:000626168500003},
      doi          = {10.1038/s41467-021-21548-y},
      url          = {https://bib-pubdb1.desy.de/record/472478},
}